![Background. An effective dosing regimen of -lactam and macrolide
antibiotics for otitis media involving S. pneumoniae (SP) requires that drug
concentrations in middle ear fluid (MEF) remain above the MIC (T>MIC) of the
isolate for at least 35-50% of the dosing interval. The purpose of these
analyses was to determine the probability of obtaining 35-50% T>MIC in MEF
using Monte Carlo simulation (MCS) for CDC-recommended (amoxicillin) or
FDA-approved dosing regimens of AMX, cefaclor, cefprozil, cefixime,
cefpodoxime, ceftibuten, ceftriaxone, and clarithromycin.
Methods. MCS (5000 subjects) was utilized to estimate the probability of
attaining a free-drug (fu) T>MIC of 35-50% of a dosing interval. Fu-drug
concentration probability density functions for each agent were estimated
using published MEF drug concentrations collected during the interval of
interest. A microbiological probability mass function for each agent was
estimated from 977 clinical isolates of SP obtained from pediatric patients < 5
years of age (SENTRY Program, 1997-2000).
Results.
Conclusions. Amoxicillin (either FDA or CDC regimens), clarithromycin and
ceftriaxone demonstrated probabilities > 80% of achieving the 35-50% T>MIC
target. Although there was great variability among oral cephalosporins in
achieving the pharmacokinetics/pharmacodynamics (PK/PD) target, none of
the agents had a probability > 65%, which may suggest that these agents are
under-dosed for the treatment of otitis media in pediatric patients involving SP;
thus, amoxicillin, ceftriaxone and clarithromycin may be preferable to oral
cephalosporins as clinical options for otitis media.
Pharmacokinetics/Pharmacodynamics in Otitis Media:
Comparison of Time-Dependent Antibiotics in Middle Ear Fluid
SM Bhavnani1,2, PG Ambrose1, CM Rubino1, A Forrest2, RN Jones3
1Cognigen Corporation, Buffalo, NY; 2SUNY at Buffalo, NY; and 3The Jones Group, North Liberty, IA
641
INTRODUCTION
Streptococcus pneumoniae remains a leading cause of morbidity and mortality
among infants and children worldwide. The incidence of penicillin-resistant
strains of S. pneumoniae is rising and has made the empirical treatment of
common respiratory tract infections such as otitis media more difficult (1-3).
Further complicating the treatment of infants and children with otitis media is
the observation that resistance to macrolides and cephalosporins among
penicillin-intermediate or -resistant strains is the norm, rather than the
exception (1, 4). When one considers that penicillin-resistance is related to
Table 1: Dosing Regimens Modeled and Simulation Assumptions
1.Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr
Infect Dis J 1996;15:255-259.
2.Dagan R. Clinical significance of resistant organisms in otitis media. Pediatr Infect Dis J
2000;19:378-382.
3.Pichichero ME. Recurrent and persistent otitis media. Pediatr Infect Dis J 2000;19:911-916.
4.Doern GV, Brueggemann A, Holley HP, Rauch AM. Antimicrobial resistance of Streptococcus
pneumoniae recovered from outpatients in the United States during the winter months of 1994 to
1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996;40:
1208-13.
5.Leibovitz, E, Raiz S, Pigliasky L, Greenberg D, Yagupsky P, Fliss DM, Leiberman A, Dagan R.
Resistance patterns of middle ear fluid isolates in acute otitis media recently treated with antibiotics.
Pediatr Infect Dis J 1998;17:463-469.
6.McLinn S, Williams D. Incidence of antibiotic-resistant Streptococcus pneumoniae and beta-
lactamase positive Haemophilus influenzae in clinical isolates from patients with otitis media. Pediatr
Infect Dis J 1996;15:S3-9.
7.Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice
and men. Clin Infect Dis 1998;26:1-12.
8.Krause PJ, Owens NJ, Nightingale CH, Klimek JJ, Lehmann WB, Quintiliani R. Penetration of
amoxicillin, cefaclor, erythromycin-sulfisoxazole, and trimethoprim-sulfamethoxazole into the middle
ear fluid of patients with chronic serious otitis media. J Infect Dis 1982; 145:815-821.
9.Eden T, Anari M, Ernstson S, Sundberg L. Penetration of cefaclor to adenoid tissue and middle ear
fluid in secretory otitis media. Scand J Infect Dis 1983; 39:48-52.
10.Shyu WC, Haddad J, Reilly J, Khan WN, Campbell DA, Tsai Y, Barbhaiya RH. Penetration of ceprozil
into middle ear fluid of patients with otitis media. Antimicrob Agents Chemother 1994; 38:2210-2212.
11.Scaglione F, Demartini G, Dugnani S, Arcidiacono MM, Pintucci JP, Fraschini F. Interpretation of
middle ear fluid concentrations of antibiotics: Comparison between ceftibuten, cefixime and
azithromycin. Br J Clin Pharmacol 1999; 47:267-271.
12.Borin MT, McCormick DP, Schwartz RH, Ryan KR. Middle ear fluid levels of cefpodoxime in pediatric
patients with acute otitis media. Annual Meeting for American Society for Clinical Pharmacology and
Therapeutics. Abstract #: PI-45. Clin Pharmacol Ther 1997; 61:148.
13.Gudnason T, Gudbrandsson F, Barsanti F, Kristinsson KG. Penetration of ceftriaxone into middle ear
fluid of children. Pediatr Infect Dis J 1998;17:258-260.
14.Gan VN, McCarthy JM, Chu S-Y, Carr R. Penetration of clarithromycin into middle ear fluid of
children with acute otitis media. Pediatr Infect Dis J 1997; 16:39-43.
REFERENCES
Figure 1: Streptococcus pneumoniae MIC Distributions for amoxicillin,
cefaclor, cefixime, cefpodoxime, cefprozil, ceftibution, ceftriaxone, and
clarithromycin (SENTRY Antimicrobial Surveillance Program)
ABSTRACT
Agent
Mean MEF (sd or
range) [g/mL]
Dosing Regimen
MIC50, MIC90,
Range [mg/L]
% Protein
Bound
PK-PD Target
Attainment [%]
2.7
0.7
8.1
2.1
0.5
(0.13-0.95)
0.25
0.06
0.8
0.2
0.5
(0.35-1.6)
2.9
1.2
19
(8-28)
8.3
2.5
15 mg/kg Q8hr 0.06, 4, 0.06->8 20 83
45 mg/kg Q12hr 0.06, 4, 0.06->8 20 95
5.8
cefprozil 15 mg/kg Q12hr 0.5, 16, 0.12->16 40 18
cefaclor 20 mg/kg Q12hr 2, >32, 0.25->32 25
32
cefpodoxime 5 mg/kg Q12hr 0.12, 4, 0.03->4 28 61
cefixime 8 mg/kg Q24hr 0.5, >4, 0.03->4 67
0.12, 2, 0.008-16 90 88
ceftibuten 9 mg/kg/d QD >4, >4, 0.25->4 65
84
amoxicillin (FDA dose)
amoxicillin (CDC dose)
clarithromycin 7.5 mg/kg Q12hr 0.25, 8, 0.25->32 60
2.8
ceftriaxone 50 mg/kg OTO
previous antibiotic therapy, common among infants and children with acute or
recurrent otitis media (2, 5, 6), then the importance of appropriate antibiotic
selection becomes apparent.
For -lactam antibiotics, the time that drug concentrations remain above the
MIC (T>MIC) of the pathogen is accepted as the
pharmacokinetics/pharmacodynamics (PK/PD) target for therapeutic efficacy
(7). There is some evidence that the T>MIC in plasma may also be associated
with drug efficacy in otitis media (1). In general, the PK/PD target for time-
dependent antibiotics is a T>MIC of 40-50% of a dosing interval. Using Monte
Carlo simulation, we have attempted to quantify the impact of the two most
important sources of variability on PK/PD target attainment: 1) the variability in
drug concentrations in the middle ear fluid (MEF) after the administration of
recommended dosage regimens of several common antibiotics in children, and
2) the variability in the S. pneumoniae sensitivity as demonstrated through
minimum inhibitory concentration (MIC) values seen clinically. This approach
has two advantages: 1) it attempts to quantify the influence of drug
concentrations at the site of infection (MEF), and 2) it utilizes the distribution of
MIC values in the population of interest (children). This analysis uses MEF
concentration and S. pneumoniae MIC distribution data from several drugs
that exhibit time-dependent antibacterial effects: amoxicillin, cefaclor, cefprozil,
cefixime, cefpodoxime, ceftibuten, ceftriaxone, and clarithromycin.
PK/PD Target Attainment Analyses
• Monte Carlo simulation was utilized to estimate the
probability of achieving the PK/PD target for CDC-
recommended amoxicillin or FDA-approved dosing
regimens of amoxicillin, cefaclor, cefprozil, cefixime,
cefpodoxime, ceftibuten, ceftriaxone, and clarithromycin.
• The PK/PD target was defined as a free-drug (fu)
concentration in the middle ear fluid (MEF) above the MIC
of the isolate for at least 35-50% of the dosing interval
(T>MIC).
• The dosing regimens modeled and simulation
assumptions for each of the above agents are shown in
Table 1.
• Five-thousand patient population simulations were
performed for each agent using Crystal Ball 2000.1,
Decisioneering, Inc., Denver, Colorado.
Clinical Isolates
• Clinical isolates of S. pneumoniae (n=977) used in the
simulations were obtained from pediatric patients < 5
years of age across North America (SENTRY
Antimicrobial Surveillance Program, 1997-2000).
METHODS
Table 3: Comparison of Overall Probability of Achieving PK/PD Target by
Dosing Regimen
Agent
Probability of Achieving
PK/PD Target (%)1
Amoxicillin (FDA dose) 83
Amoxicillin (CDC dose) 95
Cefaclor 5.8
Cefprozil 18
Cefixime 32
Cefpodoxime 61
Ceftibuten 2.8
Ceftriaxone 88
Clarithromycin 84
1Probability of achieving PK/PD target (%Time > MIC = 33-50%) based on entire MIC distribution.
amoxicillin cefaclor cefixime cefpodoxime
cefprozil ceftibutin ceftriaxone clarithromycin
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
.0008 .0015 .03 .06 .12 .25 .5 1 2 4 8 16 32 64
MIC (mg/L)
Probability
Pharmacokinetic Data
• Analyses were performed using previously published
pharmacokinetic data obtained from pediatric patients with
otitis media (8-14).
• Mean (range or standard deviation) concentrations in MEF
were obtained for %Time > MIC = 33-50% of the dosing
interval and are summarized in Table 1.
For more information, please contact:
Sujata M. Bhavnani, Pharm.D.
Cognigen Corporation
395 Youngs Road, Buffalo, NY, 14221
sujata.bhavnani@cognigencorp.com
716-633-3463, ext. 273
• The integration of PK/PD concepts with Monte Carlo Simulation
represents an advance in the paradigm of evaluating and comparing
antimicrobial regimens, both during drug development and post-
marketing.
• Due to the increasing number of resistant S. pneumoniae isolates
causing otitis media, a thorough understanding of the influence of the
variability inherent in antimicrobial treatment is critical to appropriate
dosage regimen selection.
• Amoxicillin (either FDA or CDC regimens), clarithromycin, and
ceftriaxone demonstrated overall probabilities > 80% of achieving the
PK/PD target of 35-50% T>MIC in the MEF.
• Although there was great variability among oral cephalosporins in the
overall probability of achieving the PK/PD target in the MEF, none of the
agents compared demonstrated a probability > 65%.
• The results of these analyses suggested that the oral cephalosporins
compared are generally under-dosed for the treatment of otitis media in
pediatric patients involving S. pneumoniae.
• Amoxicillin, ceftriaxone, and clarithromycin may be preferable to oral
cephalosporins as clinical options for treatment of otitis media arising
from S. pneumoniae.
DISCUSSION/CONCLUSIONS
Agent Regimen
Mean (% CV) Drug
Concentration at
33-50% of Dosing
Interval
Distribution
Assumption
fu
Amoxicillin (8)
(FDA dose)
45 mg/kg/d in 3 divided doses 2.7 (26) LN 0.80
Amoxicillin (8)
(CDC dose)
90 mg/kg/d in 2 divided doses 8.1 (26) LN 0.80
Cefaclor (9) 40 mg/kg/d in 2 divided doses 0.50 Tri 0.75
Cefixime (12) 8 mg/kg/day as a single dose 0.80 (25) LN 0.33
Cefpodoxime (11) 10 mg/kg/d in 2 divided doses 0.50 Tri 0.72
Cefprozil (10) 30 mg/kg/d in 2 divided doses 0.25 (24) LN 0.60
Ceftibuten (12) 9 mg/kg/day as a single dose 2.9 (41) LN 0.35
Ceftriaxone (13) 50 mg/kg x 1 19.0 Tri 0.10
Clarithromycin (14) 7.5 mg/kg Q 12 hr 8.3 (30) LN 0.40
HD = high dose recommended by the CDC; fu = fraction of unbound drug; LN = log normal, Tri = Triangular
• The distribution of S. pneumoniae isolates by patient age
is summarized in Table 2.
• The MIC distributions for amoxicillin, cefaclor, cefixime,
cefpodoxime, cefprozil, ceftibution, ceftriaxone, and
clarithromycin against S. pneumoniae are shown in
Figure 1.
RESULTS
Table 2: Distribution of Streptococcus pneumoniae Isolates (n=977) by
Patient Age (SENTRY Antimicrobial Surveillance Program)
Age (years)
<1
1
2
3
4
5
Total 5 years
% of Isolates
27
37
14
10
7
35
100](https://image.slidesharecdn.com/idsa641-230215233707-5a138de7/85/IDSA641-PPT-1-320.jpg)
IDSA641.PPT
- 1. Background. An effective dosing regimen of -lactam and macrolide antibiotics for otitis media involving S. pneumoniae (SP) requires that drug concentrations in middle ear fluid (MEF) remain above the MIC (T>MIC) of the isolate for at least 35-50% of the dosing interval. The purpose of these analyses was to determine the probability of obtaining 35-50% T>MIC in MEF using Monte Carlo simulation (MCS) for CDC-recommended (amoxicillin) or FDA-approved dosing regimens of AMX, cefaclor, cefprozil, cefixime, cefpodoxime, ceftibuten, ceftriaxone, and clarithromycin. Methods. MCS (5000 subjects) was utilized to estimate the probability of attaining a free-drug (fu) T>MIC of 35-50% of a dosing interval. Fu-drug concentration probability density functions for each agent were estimated using published MEF drug concentrations collected during the interval of interest. A microbiological probability mass function for each agent was estimated from 977 clinical isolates of SP obtained from pediatric patients < 5 years of age (SENTRY Program, 1997-2000). Results. Conclusions. Amoxicillin (either FDA or CDC regimens), clarithromycin and ceftriaxone demonstrated probabilities > 80% of achieving the 35-50% T>MIC target. Although there was great variability among oral cephalosporins in achieving the pharmacokinetics/pharmacodynamics (PK/PD) target, none of the agents had a probability > 65%, which may suggest that these agents are under-dosed for the treatment of otitis media in pediatric patients involving SP; thus, amoxicillin, ceftriaxone and clarithromycin may be preferable to oral cephalosporins as clinical options for otitis media. Pharmacokinetics/Pharmacodynamics in Otitis Media: Comparison of Time-Dependent Antibiotics in Middle Ear Fluid SM Bhavnani1,2, PG Ambrose1, CM Rubino1, A Forrest2, RN Jones3 1Cognigen Corporation, Buffalo, NY; 2SUNY at Buffalo, NY; and 3The Jones Group, North Liberty, IA 641 INTRODUCTION Streptococcus pneumoniae remains a leading cause of morbidity and mortality among infants and children worldwide. The incidence of penicillin-resistant strains of S. pneumoniae is rising and has made the empirical treatment of common respiratory tract infections such as otitis media more difficult (1-3). Further complicating the treatment of infants and children with otitis media is the observation that resistance to macrolides and cephalosporins among penicillin-intermediate or -resistant strains is the norm, rather than the exception (1, 4). When one considers that penicillin-resistance is related to Table 1: Dosing Regimens Modeled and Simulation Assumptions 1.Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:255-259. 2.Dagan R. Clinical significance of resistant organisms in otitis media. Pediatr Infect Dis J 2000;19:378-382. 3.Pichichero ME. Recurrent and persistent otitis media. Pediatr Infect Dis J 2000;19:911-916. 4.Doern GV, Brueggemann A, Holley HP, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996;40: 1208-13. 5.Leibovitz, E, Raiz S, Pigliasky L, Greenberg D, Yagupsky P, Fliss DM, Leiberman A, Dagan R. Resistance patterns of middle ear fluid isolates in acute otitis media recently treated with antibiotics. Pediatr Infect Dis J 1998;17:463-469. 6.McLinn S, Williams D. Incidence of antibiotic-resistant Streptococcus pneumoniae and beta- lactamase positive Haemophilus influenzae in clinical isolates from patients with otitis media. Pediatr Infect Dis J 1996;15:S3-9. 7.Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12. 8.Krause PJ, Owens NJ, Nightingale CH, Klimek JJ, Lehmann WB, Quintiliani R. Penetration of amoxicillin, cefaclor, erythromycin-sulfisoxazole, and trimethoprim-sulfamethoxazole into the middle ear fluid of patients with chronic serious otitis media. J Infect Dis 1982; 145:815-821. 9.Eden T, Anari M, Ernstson S, Sundberg L. Penetration of cefaclor to adenoid tissue and middle ear fluid in secretory otitis media. Scand J Infect Dis 1983; 39:48-52. 10.Shyu WC, Haddad J, Reilly J, Khan WN, Campbell DA, Tsai Y, Barbhaiya RH. Penetration of ceprozil into middle ear fluid of patients with otitis media. Antimicrob Agents Chemother 1994; 38:2210-2212. 11.Scaglione F, Demartini G, Dugnani S, Arcidiacono MM, Pintucci JP, Fraschini F. Interpretation of middle ear fluid concentrations of antibiotics: Comparison between ceftibuten, cefixime and azithromycin. Br J Clin Pharmacol 1999; 47:267-271. 12.Borin MT, McCormick DP, Schwartz RH, Ryan KR. Middle ear fluid levels of cefpodoxime in pediatric patients with acute otitis media. Annual Meeting for American Society for Clinical Pharmacology and Therapeutics. Abstract #: PI-45. Clin Pharmacol Ther 1997; 61:148. 13.Gudnason T, Gudbrandsson F, Barsanti F, Kristinsson KG. Penetration of ceftriaxone into middle ear fluid of children. Pediatr Infect Dis J 1998;17:258-260. 14.Gan VN, McCarthy JM, Chu S-Y, Carr R. Penetration of clarithromycin into middle ear fluid of children with acute otitis media. Pediatr Infect Dis J 1997; 16:39-43. REFERENCES Figure 1: Streptococcus pneumoniae MIC Distributions for amoxicillin, cefaclor, cefixime, cefpodoxime, cefprozil, ceftibution, ceftriaxone, and clarithromycin (SENTRY Antimicrobial Surveillance Program) ABSTRACT Agent Mean MEF (sd or range) [g/mL] Dosing Regimen MIC50, MIC90, Range [mg/L] % Protein Bound PK-PD Target Attainment [%] 2.7 0.7 8.1 2.1 0.5 (0.13-0.95) 0.25 0.06 0.8 0.2 0.5 (0.35-1.6) 2.9 1.2 19 (8-28) 8.3 2.5 15 mg/kg Q8hr 0.06, 4, 0.06->8 20 83 45 mg/kg Q12hr 0.06, 4, 0.06->8 20 95 5.8 cefprozil 15 mg/kg Q12hr 0.5, 16, 0.12->16 40 18 cefaclor 20 mg/kg Q12hr 2, >32, 0.25->32 25 32 cefpodoxime 5 mg/kg Q12hr 0.12, 4, 0.03->4 28 61 cefixime 8 mg/kg Q24hr 0.5, >4, 0.03->4 67 0.12, 2, 0.008-16 90 88 ceftibuten 9 mg/kg/d QD >4, >4, 0.25->4 65 84 amoxicillin (FDA dose) amoxicillin (CDC dose) clarithromycin 7.5 mg/kg Q12hr 0.25, 8, 0.25->32 60 2.8 ceftriaxone 50 mg/kg OTO previous antibiotic therapy, common among infants and children with acute or recurrent otitis media (2, 5, 6), then the importance of appropriate antibiotic selection becomes apparent. For -lactam antibiotics, the time that drug concentrations remain above the MIC (T>MIC) of the pathogen is accepted as the pharmacokinetics/pharmacodynamics (PK/PD) target for therapeutic efficacy (7). There is some evidence that the T>MIC in plasma may also be associated with drug efficacy in otitis media (1). In general, the PK/PD target for time- dependent antibiotics is a T>MIC of 40-50% of a dosing interval. Using Monte Carlo simulation, we have attempted to quantify the impact of the two most important sources of variability on PK/PD target attainment: 1) the variability in drug concentrations in the middle ear fluid (MEF) after the administration of recommended dosage regimens of several common antibiotics in children, and 2) the variability in the S. pneumoniae sensitivity as demonstrated through minimum inhibitory concentration (MIC) values seen clinically. This approach has two advantages: 1) it attempts to quantify the influence of drug concentrations at the site of infection (MEF), and 2) it utilizes the distribution of MIC values in the population of interest (children). This analysis uses MEF concentration and S. pneumoniae MIC distribution data from several drugs that exhibit time-dependent antibacterial effects: amoxicillin, cefaclor, cefprozil, cefixime, cefpodoxime, ceftibuten, ceftriaxone, and clarithromycin. PK/PD Target Attainment Analyses • Monte Carlo simulation was utilized to estimate the probability of achieving the PK/PD target for CDC- recommended amoxicillin or FDA-approved dosing regimens of amoxicillin, cefaclor, cefprozil, cefixime, cefpodoxime, ceftibuten, ceftriaxone, and clarithromycin. • The PK/PD target was defined as a free-drug (fu) concentration in the middle ear fluid (MEF) above the MIC of the isolate for at least 35-50% of the dosing interval (T>MIC). • The dosing regimens modeled and simulation assumptions for each of the above agents are shown in Table 1. • Five-thousand patient population simulations were performed for each agent using Crystal Ball 2000.1, Decisioneering, Inc., Denver, Colorado. Clinical Isolates • Clinical isolates of S. pneumoniae (n=977) used in the simulations were obtained from pediatric patients < 5 years of age across North America (SENTRY Antimicrobial Surveillance Program, 1997-2000). METHODS Table 3: Comparison of Overall Probability of Achieving PK/PD Target by Dosing Regimen Agent Probability of Achieving PK/PD Target (%)1 Amoxicillin (FDA dose) 83 Amoxicillin (CDC dose) 95 Cefaclor 5.8 Cefprozil 18 Cefixime 32 Cefpodoxime 61 Ceftibuten 2.8 Ceftriaxone 88 Clarithromycin 84 1Probability of achieving PK/PD target (%Time > MIC = 33-50%) based on entire MIC distribution. amoxicillin cefaclor cefixime cefpodoxime cefprozil ceftibutin ceftriaxone clarithromycin 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 .0008 .0015 .03 .06 .12 .25 .5 1 2 4 8 16 32 64 MIC (mg/L) Probability Pharmacokinetic Data • Analyses were performed using previously published pharmacokinetic data obtained from pediatric patients with otitis media (8-14). • Mean (range or standard deviation) concentrations in MEF were obtained for %Time > MIC = 33-50% of the dosing interval and are summarized in Table 1. For more information, please contact: Sujata M. Bhavnani, Pharm.D. Cognigen Corporation 395 Youngs Road, Buffalo, NY, 14221 sujata.bhavnani@cognigencorp.com 716-633-3463, ext. 273 • The integration of PK/PD concepts with Monte Carlo Simulation represents an advance in the paradigm of evaluating and comparing antimicrobial regimens, both during drug development and post- marketing. • Due to the increasing number of resistant S. pneumoniae isolates causing otitis media, a thorough understanding of the influence of the variability inherent in antimicrobial treatment is critical to appropriate dosage regimen selection. • Amoxicillin (either FDA or CDC regimens), clarithromycin, and ceftriaxone demonstrated overall probabilities > 80% of achieving the PK/PD target of 35-50% T>MIC in the MEF. • Although there was great variability among oral cephalosporins in the overall probability of achieving the PK/PD target in the MEF, none of the agents compared demonstrated a probability > 65%. • The results of these analyses suggested that the oral cephalosporins compared are generally under-dosed for the treatment of otitis media in pediatric patients involving S. pneumoniae. • Amoxicillin, ceftriaxone, and clarithromycin may be preferable to oral cephalosporins as clinical options for treatment of otitis media arising from S. pneumoniae. DISCUSSION/CONCLUSIONS Agent Regimen Mean (% CV) Drug Concentration at 33-50% of Dosing Interval Distribution Assumption fu Amoxicillin (8) (FDA dose) 45 mg/kg/d in 3 divided doses 2.7 (26) LN 0.80 Amoxicillin (8) (CDC dose) 90 mg/kg/d in 2 divided doses 8.1 (26) LN 0.80 Cefaclor (9) 40 mg/kg/d in 2 divided doses 0.50 Tri 0.75 Cefixime (12) 8 mg/kg/day as a single dose 0.80 (25) LN 0.33 Cefpodoxime (11) 10 mg/kg/d in 2 divided doses 0.50 Tri 0.72 Cefprozil (10) 30 mg/kg/d in 2 divided doses 0.25 (24) LN 0.60 Ceftibuten (12) 9 mg/kg/day as a single dose 2.9 (41) LN 0.35 Ceftriaxone (13) 50 mg/kg x 1 19.0 Tri 0.10 Clarithromycin (14) 7.5 mg/kg Q 12 hr 8.3 (30) LN 0.40 HD = high dose recommended by the CDC; fu = fraction of unbound drug; LN = log normal, Tri = Triangular • The distribution of S. pneumoniae isolates by patient age is summarized in Table 2. • The MIC distributions for amoxicillin, cefaclor, cefixime, cefpodoxime, cefprozil, ceftibution, ceftriaxone, and clarithromycin against S. pneumoniae are shown in Figure 1. RESULTS Table 2: Distribution of Streptococcus pneumoniae Isolates (n=977) by Patient Age (SENTRY Antimicrobial Surveillance Program) Age (years) <1 1 2 3 4 5 Total 5 years % of Isolates 27 37 14 10 7 35 100